ProBioGen Plans Expansion
ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.
ProBioGen AG announced that it will be investing €20 million to double its workforce in Berlin. ProBioGen develops novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The company specializes in cell line and process development up to GMP contract manufacturing and develops technologies to improve biotechnologically active substances. ProBioGen plans to exploit its internal potential for the development of production cell lines, process engineering, and GMP manufacturing of biopharmaceuticals.
"Together with our parent company, we will continue to expand and invest in Berlin," stated Wieland Wolf, CEO, in a press release. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees."
Source: ProBioGen
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
